In breast cancer cells, t-DARPP activates insulin-like growth factor 1 receptor (IGF-1R) signaling through heterodimerization with EGFR and HER2 to stimulate glycolysis and trastuzumab resistance [47]. The gene discussed is IGF1R; the disease is breast carcinoma.